Five-day Vidaza dosing shows efficacy
Azacitidine study shows five-day dosing schedule is efficacious
Preliminary analysis of a Phase II clinical trial evaluating five-day dosing schedules for azacitidine (Vidaza, Pharmion) has shown efficacy and safety that are similar to the drug?s currently recommended seven-day schedule. The data, which were presented at the 49th Annual Meeting and Exposition of the American Society of Hematology, suggest that a five-day schedule is as effective at achieving red blood cell transfusion independence in patients with Myelodysplastic Syndromes (MDS). According to Pharmion, a five-day schedule would be more convenient for patients and eliminate the need for weekend dosing. Azacitidine, a demethylating agent, was approved in 2004 as the first drug for the treatment of all five subtypes of MDS.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Improved Understanding of Hidradenitis Suppurativa Can Enhance Patient Outcomes
July 14th 2025Researchers assessed the difference between hidradenitis suppurativa and other skin conditions regarding the initiating events, inflammatory signature, and molecular and clinical features of each disease.
